About Us
The Leader of advanced Technologie
Dr. Giri Cancer Research Institute (GCRI) is a rapidly growing biotechnology and specialty chemical oriented company, which is dedicated to provide services and quality products to research institutions, immunodiagnostics and pharmaceutical companies. GCRI is started by Dr. Brij Pal Giri (Ph.D.), a resident of USA. GCRI has research and manufacturing facilities at Selaqui, Uttrakhand, India. Research laboratories are well equipped with all modern instruments. GCRI has well qualified staff for research and production and planning to work on very advance technology for early stage detection of cancer and to target the cancerous tumor selectively.
GCRI has started manufacturing the most advanced reagents in Selaqui, Uttrakhand, India. This technology is transferred from Michigan Diagnostics situated in Michigan, USA. These reagents will help the diagnostic companies to develop their diagnostic products at lower cost. These single bottle reagents are stable for at least eighteen months. Our single bottle reagent, TMB, is highly sensitive and have excellent results in ELISA. Another formulation of our TMB for blotting on membrane can be used. It gives blue color after precipitating. Single bottle p-NPP is to detect alkaline phosphatase enzyme and can be used for ELISA. It is stable for 24 months
hemiluminescence is the technique used all over the world for ultrasensitive ELISA to detect antibodies or antigens in biological fluid with the help of Alkaline Phosphatase or HRP enzyme conjugates. These reagents are used for Western Blotting (proteins), Southern Blotting (RNA) and Northern Blotting in research institution and universities. Early stage of diseases such as cancer can be detected with the help of these reagents. Our new series of ultra-sensitive 1,2-dioxetanes can detect Alkaline Phosphatase, β-Glucosidase, β-Galactosidase enzymes at very low level. These novel 1, 2-dioxetanes and Luminol based chemiluminescent substrates are protected by US Patent 6,461,876B1; 6,602,679; 6,767,716B2; 7,300,766; 7,416,898B2; 7,422,908B2; 7,781,229B2; 8.546.150; 8,822,233; 8,932,881; 9,533,974 and other pending PCT and US patent applications.